Welcome to our dedicated page for Entero Therapeutics news (Ticker: ENTO), a resource for investors and traders seeking the latest updates and insights on Entero Therapeutics stock.
News for Entero Therapeutics, Inc. (NASDAQ: ENTO) covers a company that combines late clinical-stage biopharmaceutical development with a growing presence in AI-driven energy and digital infrastructure. Company press releases describe Entero’s ongoing work on Adrulipase, a recombinant lipase enzyme for gastrointestinal indications, alongside a strategic expansion into grid-edge software and data-center power orchestration through its wholly owned subsidiary, Grid AI.
Recent ENTO news highlights several major themes. First, Entero announced the acquisition of 100% of Grid AI Corp, characterized as a grid-edge, AI-driven software and device platform that enables utilities, retailers, and large power users to dynamically manage load and distributed energy resources. Subsequent releases detail Grid AI’s Dynamic Load Shaping™, Aggregation Management Platform, and plans to support hyperscale AI data centers with power-cluster optimization, campus orchestration, and AI data-center controls.
Investors following ENTO-related news will also see updates on corporate identity and listing status. The company has reported regaining compliance with Nasdaq’s stockholders’ equity requirement following the Grid AI share exchange and has announced an intended corporate name change to GridAI Technologies Corp. with a new ticker symbol, GRDX, to better reflect its combined focus on AI, data centers, and grid-edge orchestration.
Additional news items describe Grid AI’s letters of intent with a hyperscaler AI data-center developer in the ERCOT market, integration of engineering teams such as LV Grid, and the build-out of a U.S.-based leadership team with experience in energy, power, and technology. Together, these disclosures provide a stream of updates on Entero’s GI drug development, capital markets activity, and its evolving role at the intersection of AI workloads, power grids, and digital infrastructure.
Entero Therapeutics has announced agreements with holders of its existing warrants, allowing them to exercise their warrants at a reduced price of $1.09 per share. This exercise is expected to yield approximately $1.9 million in gross proceeds. In return, these holders will receive new warrants to purchase additional shares at the same price, exercisable for five years after stockholder approval. The transaction, conducted as an at-market deal under Nasdaq rules, involves issuing new warrants for up to 3,525,348 shares. Roth Capital Partners served as the financial advisor for this transaction.
Entero Therapeutics announced that their abstract on Celiac Disease research has been accepted for oral presentation at the 20th International Celiac Disease Symposium (ICDS) in Sheffield, UK, from September 5-7, 2024. The presentation will introduce a new VCIEL scale, aimed at assessing small intestinal mucosal health in Celiac Disease patients. Jack Syage, Ph.D., the President and Chief Scientific Officer, remarked that this advancement could significantly improve the precision of monitoring and diagnosing Celiac Disease, potentially enhancing treatment effectiveness.
The ICDS event details include the presentation titled 'A Composite Mucosal Scale for Celiac Disease Encompassing Both Morphology and Inflammation'. The symposium will be held at Sheffield City Hall, and registration is available through the ICDS website.
Entero Therapeutics has announced the publication of a novel algorithm for measuring intestinal damage in celiac disease. The VCIEL scale, detailed in Clinical Gastroenterology and Hepatology, combines architectural changes and inflammation metrics to provide a more sensitive and quantitative measure of small intestinal health. This innovation promises to improve the accuracy of histological evaluations and efficacy assessments of treatments for celiac disease. The significance of VCIEL was emphasized in a special editorial, underlining its potential impact on celiac disease research and clinical trials.
Entero Therapeutics, a biopharmaceutical company specializing in gastrointestinal (GI) disease therapies, will provide a corporate update at the 2024 BIO International Convention, held from June 3-6 in San Diego, CA. The company will present on June 4 at 10:30 a.m. PDT in Presentation Theater 4. The focus will be on their Phase 3 treatment for celiac disease. Interested parties can schedule meetings via the BIO One-on-One Partnering platform.
Entero Therapeutics presented two posters highlighting celiac disease research at the 2024 Digestive Disease Week Conference. The first presentation introduced the VCIEL scale, a new quantitative measure combining the villus height to crypt depth ratio (Vh:Cd) and intraepithelial lymphocyte density (IEL), showing improved sensitivity and accuracy in diagnosing small intestinal mucosal health. The second presentation focused on gluten intake thresholds needed to trigger positive serological responses, revealing higher levels than previously thought. These findings aim to enhance diagnostics and inform Phase 3 clinical trials for latiglutenase, their investigational celiac disease treatment.